Colorectal Cancer Clinical Trials in North Carolina

Showing 121-140 of 303 trials

APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery

NCT03087591

This phase I trial studies the side effects and best dose of APN401 in treating patients with pancreatic cancer, colorectal cancer, or other solid tumors that have spread to other places in the body or have come back. APN401 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Metastatic Malignant Neoplasm in the BrainMetastatic Solid NeoplasmRecurrent Colorectal Carcinoma+9 more

Wake Forest University Health Sciences11 participantsStarted Apr 2017

Winston-Salem, North Carolina, United States

Approved For Marketing41 miles

Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer

NCT02286492

The objective of the program is to provide access to TAS-102 to patients with metastatic colorectal cancer who are refractory to or failing standard chemotherapy, are new to therapy with TAS-102 and in whom therapy with TAS-102 is clinically indicated.

Colorectal Cancer Metastatic

Taiho Oncology, Inc.

Birmingham, Alabama, United States • Scottsdale, Arizona, United States • Fresno, California, United States +30 more locations

APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery

Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer

Colorectal Cancer Trials in Other Cities

Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer

Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer

A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies

Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study

Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)

Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Scaling CRC Screening Through Outreach, Referral, and Engagement (SCORE)

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation

ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer

Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: the VAPOR-C Trial

MGD019 DART® Protein in Unresectable/Metastatic Cancer

A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

Other Conditions in North Carolina